Pulse Biosciences, Inc. (PLSE)
USD 14.48
(-4.49%)
USD 14.48
(-4.49%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -35.22 Million USD | -337.69% |
| 2022 | 14.81 Million USD | 185.34% |
| 2021 | -17.36 Million USD | -1468.56% |
| 2020 | -1.1 Million USD | -515.0% |
| 2019 | -180 Thousand USD | 99.65% |
| 2018 | -51.1 Million USD | -1409.24% |
| 2017 | -3.38 Million USD | -62.09% |
| 2016 | -2.08 Million USD | 42.07% |
| 2015 | -3.6 Million USD | 48.55% |
| 2014 | -7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -70.66 Million USD | -302.59% |
| 2024 Q2 | -17.55 Million USD | 32.46% |
| 2024 Q1 | -25.98 Million USD | 26.21% |
| 2023 Q3 | -41 Million USD | 16.54% |
| 2023 FY | -35.22 Million USD | -337.69% |
| 2023 Q4 | -35.22 Million USD | 14.1% |
| 2023 Q2 | -49.12 Million USD | -328.12% |
| 2023 Q1 | 21.53 Million USD | 45.34% |
| 2022 Q4 | 14.81 Million USD | 139.89% |
| 2022 Q2 | -4.35 Million USD | -112.96% |
| 2022 FY | 14.81 Million USD | 185.34% |
| 2022 Q3 | 6.17 Million USD | 241.9% |
| 2022 Q1 | -2.04 Million USD | 88.23% |
| 2021 Q3 | -29.91 Million USD | 13.37% |
| 2021 FY | -17.36 Million USD | -1468.56% |
| 2021 Q4 | -17.36 Million USD | 41.95% |
| 2021 Q2 | -34.53 Million USD | -360.18% |
| 2021 Q1 | -7.5 Million USD | -577.87% |
| 2020 FY | -1.1 Million USD | -515.0% |
| 2020 Q3 | 4.37 Million USD | 116.63% |
| 2020 Q2 | -26.32 Million USD | -2346.38% |
| 2020 Q1 | -1.07 Million USD | -497.78% |
| 2020 Q4 | -1.1 Million USD | -125.29% |
| 2019 Q4 | -180 Thousand USD | 96.85% |
| 2019 FY | -180 Thousand USD | 99.65% |
| 2019 Q2 | -6.88 Million USD | 0.42% |
| 2019 Q3 | -5.71 Million USD | 16.97% |
| 2019 Q1 | -6.91 Million USD | 86.46% |
| 2018 Q3 | -6.33 Million USD | 6.81% |
| 2018 Q4 | -51.1 Million USD | -707.19% |
| 2018 FY | -51.1 Million USD | -1409.24% |
| 2018 Q1 | -10.66 Million USD | -215.03% |
| 2018 Q2 | -6.79 Million USD | 36.31% |
| 2017 Q3 | -32.42 Million USD | -1529.3% |
| 2017 Q2 | -1.99 Million USD | 27.66% |
| 2017 Q4 | -3.38 Million USD | 89.56% |
| 2017 FY | -3.38 Million USD | -62.09% |
| 2017 Q1 | -2.75 Million USD | -31.69% |
| 2016 Q4 | -2.08 Million USD | 54.86% |
| 2016 Q2 | -20.21 Million USD | -860.29% |
| 2016 Q3 | -4.62 Million USD | 77.1% |
| 2016 Q1 | -2.1 Million USD | 41.62% |
| 2016 FY | -2.08 Million USD | 42.07% |
| 2015 Q4 | -3.6 Million USD | 27.14% |
| 2015 FY | -3.6 Million USD | 48.55% |
| 2015 Q1 | 7 Million USD | 200.0% |
| 2015 Q3 | -4.94 Million USD | 0.0% |
| 2014 FY | -7 Million USD | 0.0% |
| 2014 Q4 | -7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | 1464.626% |
| AngioDynamics, Inc. | -70.14 Million USD | 49.786% |
| AtriCure, Inc. | -9.81 Million USD | -258.812% |
| Avinger, Inc. | 10.12 Million USD | 448.034% |
| Azenta, Inc. | -618.47 Million USD | 94.305% |
| BioLife Solutions, Inc. | 7.25 Million USD | 585.606% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 101.439% |
| Daxor Corporation | 755.65 Thousand USD | 4760.965% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | -2295.986% |
| Femasys Inc. | -15.01 Million USD | -134.569% |
| GlucoTrack, Inc. | -4.29 Million USD | -719.856% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 191.507% |
| Hologic, Inc. | 374.4 Million USD | 109.407% |
| ICU Medical, Inc. | 1.45 Billion USD | 102.428% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 98.676% |
| KORU Medical Systems, Inc. | -7.03 Million USD | -400.503% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | -580.731% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -721.491% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -721.491% |
| Masimo Corporation | 804 Million USD | 104.381% |
| Microbot Medical Inc. | -2.28 Million USD | -1440.726% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | -267.048% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 111.654% |
| Nephros, Inc. | -2.47 Million USD | -1325.374% |
| NovoCure Limited | 355.42 Million USD | 109.91% |
| NEXGEL, Inc. | 98 Thousand USD | 36039.796% |
| NEXGEL, Inc. | 98 Thousand USD | 36039.796% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 159.641% |
| OraSure Technologies, Inc. | -276.9 Million USD | 87.28% |
| Pro-Dex, Inc. | 10.91 Million USD | 422.655% |
| Predictive Oncology Inc. | -5.87 Million USD | -499.828% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | 1262.723% |
| QuidelOrtho Corporation | 2.49 Billion USD | 101.412% |
| Repligen Corporation | -39.51 Million USD | 10.876% |
| Sanara MedTech Inc. | 6.64 Million USD | 630.046% |
| STAAR Surgical Company | -147.2 Million USD | 76.073% |
| Sharps Technology, Inc. | -3.01 Million USD | -1069.004% |
| Utah Medical Products, Inc. | -92.52 Million USD | 61.934% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 101.792% |
| Jin Medical International Ltd. | -2.81 Million USD | -1150.52% |